Non-Small Cell Lung Cancer Treatment Market Highlights 2020-2029
The non-small cell lung cancer treatment market is estimated to grow with a high CAGR during the forecast period, i.e., 2021-2029. The rising prevalence of non-small cell lung cancer, along with the growing awareness about the disease are expected to fuel the progress of this market. The growth of the market can also be attributed to factors such as the increase in share of smoking population and the greater exposure to toxins on a global level. According to the data collected from World Health Organization, in 2020, the estimated new cases and number of deaths from lung cancer globally, were 2.21 million and 1.80 million, respectively.
The market is segmented on the basis of treatment type into surgery, radiofrequency ablation, radiation therapy, chemotherapy, targeted therapy, immunotherapy, and others, out of which, the targeted therapy segment is anticipated to grab the largest share by the end of 2021 on account of higher adoption rates and better efficiency of targeted therapy than chemotherapy. Moreover, targeted therapy is widely being used as an adjuvant treatment alongside chemotherapy, which is also projected to contribute to the growth of the segment during the forecast period. CLICK TO DOWNLOAD SAMPLE REPORT
On the basis of end-user, the general medical & surgical hospitals’ segment in the global non-small cell lung cancer treatment market is projected to grow with a significant CAGR over the forecast period. The growth of the segment can be attributed to the fact that general medical & surgical hospitals have well-developed healthcare infrastructure due to their better financial capabilities, which leads to greater proportion of population affected with non-small cell lung cancer choosing this segment for treatment.
Non-Small Cell Lung Cancer Treatment Market Regional Synopsis
Geographically, the market is segmented into North America, Latin America, Europe, Asia Pacific and the Middle East & Africa region. The market in the Asia Pacific is predicted to grow at the highest CAGR over the forecast period owing to the increasing diagnosis rates of non-small cell lung cancer and the need to develop innovative treatment solutions in the region. Furthermore, in 2021, the market in North America is evaluated to occupy the largest share in terms of revenue, owing to the growing investment of governmental and non-governmental agencies in lung cancer research, accompanied by the presence of leading healthcare service providers in the region. Along with this, North America also leads in terms of adoption of advanced immunotherapies along with other therapies, which is also expected to contribute to the market growth in the region. Alternatively, the market in Europe is also anticipated to occupy a significant share in the non-small cell lung cancer treatment market on account of its proven success in terms of research & development and a high prevalence of non-small lung cancer in the region. In Europe, lung cancer is the leading cause of cancer-related deaths and about 85% of all lung cancer cases are classified as those of non-small cell lung cancer.
The global non-small cell lung cancer treatment market is further classified on the basis of region as follows:
- North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
- Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
- Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
- Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis
- Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis
Market Segmentation
Our in-depth analysis of the global non-small cell lung cancer treatment market includes the following segments:
By Treatment Type
- Surgery
- Radiofrequency Ablation
- Radiation Therapy
- Chemotherapy
- Targeted Therapy
- Immunotherapy
- Others
By End-User
- General Medical & Surgical Hospitals
- Specialty Hospitals
- Clinics
- Others
Growth Drivers
- Rising Prevalence of Non-Small Cell Lung Cancer
- Growing Awareness about the Disease
Challenges
- Limited Treatment Options for Non-Small Cell Lung Cancer
- Lack of Awareness About the Disease in Lower Economic Regions
Top Featured Companies Dominating the Market
- Genentech, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Celgene Corporation (Bristol Myers Squibb)
- AstraZeneca plc
- Elli Lilly & Company
- Pfizer, Inc.
- Sanofi
- Astellas Pharma, Inc.
- Novartis AG
- Takeda Oncology
